Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.31 |
| ▸ | USP36 | Q9P275 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4513641 | 1.00 | POLB (0.34) | POLBMAPTDRD2HTR2ADRD3 | |
| SCHEMBL4519090 | 0.91 | POLB (0.34) | POLBMAPTDRD2HTR2ADRD3 | |
| SCHEMBL4519475 | 0.91 | POLB (0.34) | POLBMAPTDRD2HTR2ADRD3 | |
| SCHEMBL4514681 | 0.84 | CNR2 (0.37) | POLBMAPTDRD2HTR2ADRD3 | |
| SCHEMBL23652952 | 0.75 | POLB (0.53) | POLBMAPTLMNAMTNR1ATP53 | |
| SCHEMBL4508616 | 0.75 | POLB (0.53) | POLBMAPTLMNAMTNR1ATP53 | |
| SCHEMBL4519989 | 0.73 | DRD2 (0.35) | DRD2HTR2ADRD3MTNR1AKDM4E | |
| SCHEMBL4521563 | 0.72 | MTNR1A (0.36) | POLBMAPTLMNAMTNR1AKDM4E | |
| SCHEMBL4529640 | 0.68 | TP53 (0.44) | POLBMAPTTP53 | |
| SCHEMBL2287535 | 0.67 | CA1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099187-A1 | Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| EP-1888518-A1 | NOVEL 8-SULFONYL-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR | AstraZeneca AB (SE) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006126938-A1 | NOVEL 8-SULFONYL-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099187-A1 | Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor | HTR6, HTR1D, HTR1A | POLB 4660/4885MAPT 2173/4885DRD2 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.